5 резултати
CROSS-REFERENCE TO RELATED APPLICATIONS
The present application is a national stage filing under 35 U.S.C. .sctn. 371 of PCT/EP2015/073176, filed on 7 Oct. 2015, and claims the benefit of priority to European Patent Application No. 14188063.3, filed 8 Oct. 2014. Each application is incorporated
BACKGROUND OF THE INVENTION
Cell proliferation requires the transfer of mevalonate pathway intermediates to a group of proteins, small G-proteins and the nuclear lamins among others. Agents targeted to the inhibition of the transfer process (farnesylation, geranylgeranylation), e.g., farnesyl
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to a method of inhibiting protein kinase C function and to compounds and compositions suitable for use in such a method.
2. Background Information
In mouse skin, phorbol esters exert tumor promoting, inflammatory,
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to a method of inhibiting protein kinase C function and to compounds and compositions suitable for use in such a method.
2. Background Information
In mouse skin, phorbol esters exert tumor promoting, inflammatory,
This is the U.S. national stage entry under 35 U.S.C. .sctn. 371 of PCT/GB94/00088, filed Jan. 19, 1994.
FIELD OF THE INVENTION
This invention relates to a series of carbohydrate-based compounds which are useful as anti-inflammatory agents and as agents for the control of tumour metastasis, to the